Clinical Trial Update: A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing platinum-based therapy with dostarlimab (TSR-042) and niraparib versus standard platinum-based therapy as first-line treatment fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-31